| 1 |
Frederico SC, Zhang X, Hu B, Kohanbash G. Pre-clinical models for evaluating glioma targeted immunotherapies. Front Immunol 2022;13:1092399. [PMID: 36700223 DOI: 10.3389/fimmu.2022.1092399] [Reference Citation Analysis]
|
| 2 |
Frederico SC, Darling C, Bielanin JP, Dubinsky AC, Zhang X, Hadjipanayis CG, Kohanbash G. Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier. Front Immunol 2023;14:1057567. [PMID: 36875096 DOI: 10.3389/fimmu.2023.1057567] [Reference Citation Analysis]
|
| 3 |
Giotta Lucifero A, Luzzi S. Emerging immune-based technologies for high-grade gliomas. Expert Rev Anticancer Ther 2022. [PMID: 35924820 DOI: 10.1080/14737140.2022.2110072] [Reference Citation Analysis]
|
| 4 |
Mensali N, Inderberg EM. Emerging Biomarkers for Immunotherapy in Glioblastoma. Cancers (Basel) 2022;14:1940. [PMID: 35454848 DOI: 10.3390/cancers14081940] [Reference Citation Analysis]
|
| 5 |
Mojsilovic SS, Mojsilovic S, Villar VH, Santibanez JF. The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy? Anal Cell Pathol (Amst) 2021;2021:5523055. [PMID: 34476174 DOI: 10.1155/2021/5523055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Frederico SC, Hancock JC, Brettschneider EES, Ratnam NM, Gilbert MR, Terabe M. Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma. Front Oncol 2021;11:672508. [PMID: 34041034 DOI: 10.3389/fonc.2021.672508] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 7 |
Dees KJ, Koo H, Humphreys JF, Hakim JA, Crossman DK, Crowley MR, Nabors LB, Benveniste EN, Morrow CD, McFarland BC. Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma. Neurooncol Adv 2021;3:vdab023. [PMID: 33758825 DOI: 10.1093/noajnl/vdab023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Liu J, Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China, Zhang X, Ye T, Dong Y, Zhang W, Wu F, Bo H, Shao H, Zhang R, Shen H, Department of Radiation Oncology, Dongguan People's Hospital, Affiliated Dongguan Hospital of Southern Medical University, Dongguan, Guangdong 523059, China. Prognostic modeling of patients with metastatic melanoma based on tumor immune microenvironment characteristics. MBE 2021;19:1448-1470. [DOI: 10.3934/mbe.2022067] [Reference Citation Analysis]
|
